shares of Ocugen Inc (OCGN) on
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 49 full-time employees. The firm offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The firm is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The firm is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).